Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.

Author: AnandAsha, MadabhaviIrappa, PanchalHarsha, ParikhSonia, PatelApurva

Paper Details 
Original Abstract of the Article :
About 4% of non-small-cell lung carcinomas involve an EML4-ALK tyrosine kinase fusion gene and occur almost absolutely in carcinomas arising in non-smokers. Crizotinib, the first inhibitor of anaplastic lymphoma kinase (ALK), ROS1 and c-Met receptor kinase, has been used in the treatment of ALK-posi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/crj.12550

データ提供:米国国立医学図書館(NLM)

Crizotinib Resistance: A Camel's Journey Through the Desert of Lung Cancer

The field of [oncology] is constantly seeking effective treatments for lung cancer. This study presents a rare case report of central retinal artery occlusion (CRAO) as an early sign of crizotinib resistance in an ALK-positive adenocarcinoma of the lung. Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and c-Met receptor kinase, has proven effective in treating ALK-positive non-small cell lung cancer. However, the patient in this report developed sudden onset left-sided vision loss after nine months of crizotinib therapy. Fundoscopic examination revealed a 'cherry red spot' and fundus fluorescein angiography confirmed CRAO. Although visual disorders are known side effects of crizotinib, CRAO has not been previously documented. The authors speculate that CRAO may be a sign of early crizotinib resistance, as the patient had no history of prothrombotic state.

Navigating the Shifting Sands of Cancer Treatment: A Camel's Perspective

This case report highlights the importance of vigilance in monitoring patients on targeted therapies, such as crizotinib. The development of CRAO, a rare but potentially serious side effect, raises questions about the long-term effects and potential mechanisms of resistance to crizotinib. Further research is necessary to understand the relationship between CRAO and crizotinib resistance, potentially leading to improved treatment strategies and better outcomes for patients with ALK-positive lung cancer.

The Importance of Vigilance in Cancer Treatment: A Camel's Journey

This case report reminds us that the desert of cancer treatment is vast and complex. Just as a camel must be vigilant for potential dangers, healthcare professionals must carefully monitor patients on targeted therapies for any signs of resistance or adverse effects. This case serves as a reminder of the importance of early detection and intervention in managing cancer, potentially improving outcomes for patients.

Dr. Camel's Conclusion

This case report underscores the importance of careful monitoring and vigilance in cancer treatment. As a camel navigating the desert, we must be attentive to our surroundings. Similarly, healthcare professionals must be vigilant for any signs of resistance or adverse effects in patients receiving targeted therapies. This case serves as a reminder that the journey through cancer treatment is often unpredictable and requires careful attention to detail.

Date :
  1. Date Completed 2018-09-10
  2. Date Revised 2019-02-21
Further Info :

Pubmed ID

27606884

DOI: Digital Object Identifier

10.1111/crj.12550

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.